---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-001205"
form_type: "8-K"
ticker: "RNAC"
cik: "0001453687"
company_name: "Cartesian Therapeutics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:11:33.132512+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cartesian reports positive 12-month Phase 2a data for Descartes-08 in MG; cash $118M

## Summary
- 12-month follow-up: 5 of 7 Phase 2a MG patients maintained clinically meaningful improvements ~10 months after last infusion; autoantibodies durably reduced.
- Descartes-08 well-tolerated with no dose-limiting toxicities, cytokine release syndrome, or neurotoxicity; outpatient administration without lymphodepletion.
- Phase 2b topline data expected mid-2024; Phase 2 study in SLE to initiate 1H24; IND cleared for next-gen Descartes-15 for multiple myeloma.
- Pro forma cash ~$118M as of Dec 31, 2023; expected to fund operations into 2H 2026, through Phase 3 of Descartes-08.
- Common shares outstanding: 161.9M; Series A preferred convertible into ~534.3M common shares.

## SEC filing metadata
- accession: 0001140361-24-001205
- form_type: 8-K
- ticker: RNAC
- cik: 0001453687
- company_name: Cartesian Therapeutics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1453687/000114036124001205/0001140361-24-001205-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1453687/000114036124001205/ny20014884x2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-001205
- JSON: https://secwatch.observer/filing/0001140361-24-001205.json
- Plain text: https://secwatch.observer/filing/0001140361-24-001205.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.